转自:新康界7月15日,此前已宣布将从港股私有化退市的中国中药及复宏汉霖先后公告披露最新进展。其中,由于私有化尚有相关前提条件未达成,复宏汉霖关于私有化建议的综合文件需要延迟寄发。中国中药方面,目前要约代表人则已编制相关文件并持续与有关当局联络,以达成私有化的先决条件。而赶在上述两家企业之前,聚焦肿瘤和重症感染领域的生物制药公司赛生药业已于7月5日以118亿港元的代价正式挥别港交所,并掀起了一场...
Source Link转自:新康界7月15日,此前已宣布将从港股私有化退市的中国中药及复宏汉霖先后公告披露最新进展。其中,由于私有化尚有相关前提条件未达成,复宏汉霖关于私有化建议的综合文件需要延迟寄发。中国中药方面,目前要约代表人则已编制相关文件并持续与有关当局联络,以达成私有化的先决条件。而赶在上述两家企业之前,聚焦肿瘤和重症感染领域的生物制药公司赛生药业已于7月5日以118亿港元的代价正式挥别港交所,并掀起了一场...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.